Precigen (NASDAQ:PGEN) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Precigen (NASDAQ:PGEN) in a research report released on Friday,Benzinga reports. The brokerage currently has a $4.00 price objective on the biotechnology company’s stock. HC Wainwright also issued estimates for Precigen’s FY2026 earnings at $0.01 EPS, FY2027 earnings at $0.22 EPS and FY2028 earnings at $0.39 EPS.

A number of other research analysts also recently weighed in on PGEN. StockNews.com raised shares of Precigen to a “sell” rating in a research report on Thursday, August 1st. JMP Securities reduced their target price on shares of Precigen from $14.00 to $7.00 and set a “market outperform” rating for the company in a research report on Thursday, August 15th. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $7.00.

Precigen Trading Down 7.1 %

PGEN stock traded down $0.06 during trading on Friday, reaching $0.82. The stock had a trading volume of 1,777,639 shares, compared to its average volume of 741,176. Precigen has a one year low of $0.78 and a one year high of $1.93. The company’s 50 day moving average is $0.92 and its two-hundred day moving average is $1.24.

Precigen (NASDAQ:PGEN) last issued its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). Precigen had a negative return on equity of 112.05% and a negative net margin of 3,521.68%. The firm had revenue of $0.72 million during the quarter, compared to the consensus estimate of $1.28 million. Research analysts anticipate that Precigen will post -0.44 EPS for the current fiscal year.

Institutional Trading of Precigen

A number of institutional investors have recently modified their holdings of the business. ClariVest Asset Management LLC lifted its stake in shares of Precigen by 2.9% during the 2nd quarter. ClariVest Asset Management LLC now owns 492,152 shares of the biotechnology company’s stock valued at $778,000 after buying an additional 13,752 shares in the last quarter. SG Americas Securities LLC lifted its stake in shares of Precigen by 44.2% during the 3rd quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 13,823 shares in the last quarter. Exchange Traded Concepts LLC lifted its stake in shares of Precigen by 10.2% during the 3rd quarter. Exchange Traded Concepts LLC now owns 167,496 shares of the biotechnology company’s stock valued at $159,000 after buying an additional 15,525 shares in the last quarter. Stifel Financial Corp lifted its stake in shares of Precigen by 94.9% during the 3rd quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 15,680 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Precigen by 40.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 56,998 shares of the biotechnology company’s stock valued at $90,000 after buying an additional 16,486 shares in the last quarter. 33.51% of the stock is currently owned by hedge funds and other institutional investors.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.